Table 2.
Neoadjuvant therapy-related adverse events (Common Terminology Criteria for Adverse Events Version 5.0) and surgical-related adverse events (Clavien‒Dindo) in the 20 patients
| Adverse event | N (%) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade ≥3 | |
| Skin (rash, dryness, dermatitis) | 0 | 1 (5%) | 0 |
| Pain (lymph node and oral) | 3 (15%) | 1 (5%) | 0 |
| Colitis/Diarrhoea | 1 (5%) | 1 (5%) | 0 |
| Fatigue | 3 (15%) | 0 | 0 |
| Proteinuria | 3 (15%) | 3 (15%) | 0 |
| Hypertension | 1 (5%) | 3 (15%) | 0 |
| Hyperbilirubinemia | 7 (35%) | 1 (5%) | 0 |
| Thrombocytopenia | 6 (30%) | 1 (5%) | 0 |
| Leukopenia | 2 (10%) | 1 (5%) | 0 |
| Increased AST level | 3 (15%) | 0 | 0 |
| Reactive capillary haemangiomas | 3 (15%) | 0 | 0 |
| Surgical toxic effects–Clavien‒Dindo scoring | 4 (20%) | 0 | 0 |
AST aspartate aminotransferase.